Editas Medicine, Inc. (NASDAQ:EDIT) Closed 12.7% Above Its 50 Day Moving AverageModern ReadersCRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotell… Continue reading
Editas Medicine, Inc. (NASDAQ:EDIT) Closed 12.7% Above Its 50 …Modern ReadersThe stock is trading at $20.59 which is well above the 50 day moving average which is $18.27 and marginally over the 200 day moving average of $19.21.Editas Medicine, Inc. (… Continue reading
Takeda to partner with cancer immunotherapy startupThe Japan TimesTakeda Pharmaceutical Co. has entered into a collaboration with Tokyo-based startup Noile-Immune Biotech Inc. on research and development for cancer immunotherapy. Noile-Immune Biotech w… Continue reading
STAT |
Does the world really need a journal of CRISPR?
STAT n just a few years, CRISPR, the revolutionary gene editing technology, has become science’s “it” discipline, giving birth to a bitter patent dispute, billions in biotech investments, and an in-development primetime TV drama 1. But unlike the … |
Salon |
Pioneering cancer gene therapy gets green light — and $475000 price tag
Salon The country’s first approved gene therapy — approved Wednesday to fight leukemia that resists standard therapies — will cost $475,000 for a one-time treatment, its manufacturer announced. Switzerland-based Novartis, which makes the innovative therapy … |
Salon |
Pioneering cancer gene therapy gets green light and $475000 – Salon
Salon The country’s first approved gene therapy — approved Wednesday to fight leukemia that resists standard therapies — will cost $475,000 for a one-time treatment … FDA approves ‘transformative’ type of gene therapyJordan Times First gene therapy for cancer approved: What health execs should knowModernMedicine FDA approves first gene therapy in the United StatesPharmacy Today, American Pharmacists Association, pharmacist.com Shanghai Daily (subscription) all 19 news articles » |
|
Stem cell transplant to be launched
Himalayan Times Patients who need a stem cell transplant and can’t find a donor who matches their tissue type will benefit from the transplant. Haploidentical transplant is a modified form of stem cell transplant in which a healthy first degree relative — a parent … |